LOW
45
2
CTSH
54
2
AVGO
42
-2
GT
51
22
CLX
62
-2
AMAT
41
-9
VZ
40
-2
PH
73
3
NEM
69
-2
VNO
57
5
K
65
2
ICE
73
-2
LEG
37
6
MSI
35
-11
SIG
49
15
DD
56
-4
VTR
60
5
FRT
51
-12
RCL
76
3
DFS
62
3
LOW
45
2
CTSH
54
2
AVGO
42
-2
GT
51
22
CLX
62
-2
AMAT
41
-9
VZ
40
-2
PH
73
3
NEM
69
-2
VNO
57
5
K
65
2
ICE
73
-2
LEG
37
6
MSI
35
-11
SIG
49
15
DD
56
-4
VTR
60
5
FRT
51
-12
RCL
76
3
DFS
62
3
Financhill
Back

Marcus & Millichap 10K Form

Sell
37

MMI
Marcus & Millichap

Last Price:
$37.81
Seasonality Move:
-2.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MMI News And Ratings

See the #1 stock for the next 7 days that we like better than MMI

MMI Financial Statistics

Sales & Book Value

Annual Sales: $696.1M
Cash Flow: $13.2M
Price / Cash Flow: 0
Annual Sales: $16.23
Price / Book: 2.47

Profitability

EPS (TTM): -0.32000
Net Income (TTM): $-12.4M
Gross Margin: $264.6M
Return on Equity: -1.97%
Return on Assets: -1.46%

Marcus & Millichap Earnings Forecast

Key Marcus & Millichap Financial Ratios

  • The Gross Profit Margin over the past 16 years for MMI is 38.01%.
  • The Selling, General & Administrative Expenses for MMI have been equal to 40.36% of Gross Profit Margin.
  • The Research & Development expenses have been 0.00% of Revenue.
  • The Net Earning history of MMI is -1.78% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Marcus & Millichap Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Real Estate Management & Development
Sector: Real Estate
Current Symbol: MMI
CUSIP: 566324
Website: marcusmillichap.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.08
Quick Ratio: 2.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 46.79

MMI Technical Analysis vs Fundamental Analysis

Sell
37
Marcus & Millichap (MMI) is a Sell

Is Marcus & Millichap a Buy or a Sell?

  • Marcus & Millichap stock is rated a Sell
    The current Marcus & Millichap [MMI] share price is $39.30. The Score for MMI is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.